

# George Papatheodoridis

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4080101/george-papatheodoridis-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

398  
papers

20,773  
citations

64  
h-index

136  
g-index

501  
ext. papers

24,799  
ext. citations

5  
avg, IF

7.31  
L-index

#	Paper	IF	Citations
398	Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B.. <i>Virology Journal</i> , <b>2022</b> , 19, 22	6.1	0
397	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	6
396	Lower Risk of HCC with Tenofovir than Entecavir Treatment in Subsets of Chronic Hepatitis B Patients: An updated Meta-analysis.. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2022</b> ,	4	2
395	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. <i>JHEP Reports</i> , <b>2022</b> , 4, 100409	10.3	4
394	The changing epidemiology of hepatocellular carcinoma in Greece.. <i>Annals of Gastroenterology</i> , <b>2022</b> , 35, 88-94	2.2	0
393	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2022</b> , 7, 396-415	18.8	11
392	Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs. <i>Annals of Gastroenterology</i> , <b>2021</b> , 34, 73-79	2.2	2
391	Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications. <i>Saudi Journal of Gastroenterology</i> , <b>2021</b> , 27, 319-330	3	1
390	Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study). <i>Gastroenterology</i> , <b>2021</b> ,	13.3	9
389	Risk of HBV reactivation during therapies for HCC: A systematic review.. <i>Hepatology</i> , <b>2021</b> ,	11.2	1
388	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	5
387	Comparative Utility of Transient and 2D Shear Wave Elastography for the Assessment of Liver Fibrosis in Clinical Practice. <i>Journal of Digital Imaging</i> , <b>2021</b> , 34, 1342	5.3	1
386	Serum zonulin levels in patients with liver cirrhosis: Prognostic implications. <i>World Journal of Hepatology</i> , <b>2021</b> , 13, 1394-1404	3.4	1
385	Association of cardiovascular factors in diabetic patients with non-alcoholic fatty liver disease. <i>Hormones</i> , <b>2021</b> , 1	3.1	0
384	Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues. <i>Liver International</i> , <b>2021</b> , 41, 48-57	7.9	1
383	Intrahepatic recurrence of hepatocellular carcinoma after resection: an update. <i>Clinical Journal of Gastroenterology</i> , <b>2021</b> , 14, 699-713	1.1	10
382	Antiviral prophylaxis against hepatitis B recurrence after liver transplantation: Current concepts. <i>Liver International</i> , <b>2021</b> , 41, 1448-1461	7.9	2

381	Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 1	4	2
380	SARS-CoV-2 Molecular Transmission Clusters and Containment Measures in Ten European Regions during the First Pandemic Wave. <i>Life</i> , <b>2021</b> , 11,	3	4
379	Response to Anti- <del>47</del> Blockade in Patients With Ulcerative Colitis Is Associated With Distinct Mucosal Gene Expression Profiles at Baseline. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> ,	4.5	2
378	Is hepatitis delta underestimated?. <i>Liver International</i> , <b>2021</b> , 41 Suppl 1, 38-44	7.9	2
377	Current status of hepatitis delta. <i>Current Opinion in Pharmacology</i> , <b>2021</b> , 58, 62-67	5.1	3
376	High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1896-1904	0.7	4
375	New concepts regarding finite oral antiviral therapy for HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 1495-1496	13.4	1
374	Assessment of dietary habits and the adequacy of dietary intake of patients with cirrhosis-the KIRRHOS study. <i>Clinical Nutrition</i> , <b>2021</b> , 40, 3992-3998	5.9	1
373	The burden and management of anemia in Greek patients with inflammatory bowel disease: a retrospective, multicenter, observational study. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 269	3	2
372	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , <b>2021</b> , 3, 100290	10.3	0
371	Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B". <i>Journal of Hepatology</i> , <b>2021</b> , 74, 246-247	13.4	
370	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 12-19	3.4	12
369	Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 464-474	3.4	1
368	A transient early HBV-DNA increase during PEG-IFN <del>4</del> therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 410-419	3.4	1
367	Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFN <del>4</del> -based antiviral treatment of hepatitis delta: Results from the HIDIT-II study. <i>Liver International</i> , <b>2021</b> , 41, 295-299	7.9	8
366	Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1109-1116	13.4	39
365	Microalbuminuria in NAFLD patients: The impact of cardiovascular system. <i>Liver International</i> , <b>2021</b> , 41, 1164-1165	7.9	
364	New prognostic score based on galectin-3 has similar performance to model for end-stage liver disease and sodium score in patients with stable decompensated cirrhosis. <i>Annals of Gastroenterology</i> , <b>2021</b> , 34, 728-735	2.2	0

363	Chronic Hepatitis B Virus Infection: Interferon Therapy and Long-Term Outcomes <b>2021</b> , 267-285		0
362	Platelet activation and hypercoagulability in patients with early primary biliary cholangitis compared with healthy controls. <i>Annals of Gastroenterology</i> , <b>2021</b> , 34, 229-234	2.2	
361	Management of Patients with Renal Impairment: Direct-Acting Antivirals and Renal Function <b>2021</b> , 175-190		
360	One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. <i>Hepatology International</i> , <b>2021</b> , 15, 105-113	8.8	0
359	Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. <i>Microorganisms</i> , <b>2021</b> , 9,	4.9	2
358	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	1
357	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 770-785	13.4	19
356	COVID-19 pandemic and worldwide organ transplantation: a population-based study. <i>Lancet Public Health, The</i> , <b>2021</b> , 6, e709-e719	22.4	29
355	Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	2
354	Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. <i>Annals of Gastroenterology</i> , <b>2021</b> , 34, 404-414	2.2	3
353	ssHepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicenter cohort study. <i>Liver International</i> , <b>2021</b> ,	7.9	0
352	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	17
351	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1037-1045	13.4	34
350	Efficacy and safety of new direct-acting antivirals in kidney transplant recipients with chronic hepatitis C: a single-center study. <i>Annals of Gastroenterology</i> , <b>2020</b> , 33, 285-292	2.2	3
349	Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG-101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participants. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 699-708	3.4	7
348	Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine. <i>Hepatology</i> , <b>2020</b> , 72, 2197-2205	11.2	12
347	Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B. <i>Cells</i> , <b>2020</b> , 9,	7.9	13
346	New epidemiology of hepatitis delta. <i>Liver International</i> , <b>2020</b> , 40 Suppl 1, 48-53	7.9	15

345	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1088-1096	13.4	50
344	Reply to: "Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy". <i>Journal of Hepatology</i> , <b>2020</b> , 73, 223-224	13.4	
343	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , <b>2020</b> , 40, 1841-1852	7.9	28
342	Phase IIa safety and efficacy of milciclib, a pan-cyclin dependent kinase inhibitor, in unresectable, sorafenib-refractory or -intolerant hepatocellular carcinoma patients.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e16711-e16711	2.2	4
341	Validation of cutoffs for skeletal muscle mass index based on computed tomography analysis against dual energy X-ray absorptiometry in patients with cirrhosis: the KIRRHOS study. <i>Annals of Gastroenterology</i> , <b>2020</b> , 33, 80-86	2.2	3
340	Design and Development of a Viral Hepatitis and HIV Infection Screening Program (Hprolipsis) for the General, Greek Roma, and Migrant Populations of Greece: Protocol for Three Cross-Sectional Health Examination Surveys. <i>JMIR Research Protocols</i> , <b>2020</b> , 9, e13578	2	1
339	The significance of C-reactive protein to albumin ratio in patients with decompensated cirrhosis. <i>Annals of Gastroenterology</i> , <b>2020</b> , 33, 667-674	2.2	1
338	Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 118-126	3.4	20
337	Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. <i>Liver International</i> , <b>2020</b> , 40, 484-495	7.9	24
336	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 539-557	13.4	88
335	Persistence and adherence to nucleos(t)ide analogues in chronic hepatitis B: a multicenter cohort study. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 635-641	2.2	3
334	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , <b>2020</b> , 40, 260-270	7.9	14
333	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , <b>2020</b> , 98, 106175	2.3	28
332	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1368-1378	13.4	41
331	Cellular senescence and hepatitis B-related hepatocellular carcinoma: An intriguing link. <i>Liver International</i> , <b>2020</b> , 40, 2917-2927	7.9	7
330	An Evaluation of Diagnosis-Related Group (DRG) Implementation Focused on Cancer DRGs in Greek Public Hospitals. <i>PharmacoEconomics - Open</i> , <b>2020</b> , 4, 61-69	2.1	2
329	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 14-24	13.4	75
328	Comparison of the Uptake of Screening Colonoscopy between Physicians and the General Population in Greece. <i>Digestive Diseases</i> , <b>2020</b> , 38, 23-30	3.2	2

327	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. <i>PLoS ONE</i> , <b>2020</b> , 15, e0230893	3.7	1
326	High prevalence of asymptomatic peptic ulcers diagnosed during screening endoscopy in patients with cirrhosis. <i>Annals of Gastroenterology</i> , <b>2019</b> , 32, 451-456	2.2	4
325	Evaluation of the effectiveness of eight screening tools in detecting risk of malnutrition in cirrhotic patients: the KIRRHOS study. <i>British Journal of Nutrition</i> , <b>2019</b> , 122, 1368-1376	3.6	13
324	Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 697-709	3.4	10
323	Liver transplantation using hepatitis B core positive grafts: Which is the optimal antiviral prophylaxis?. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 635-636	13.4	2
322	Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. <i>Liver International</i> , <b>2019</b> , 39, 1837-1844	7.9	8
321	GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e1-e2	13.4	10
320	GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e2-e3	13.4	9
319	Role of Spleen Stiffness Measurement by 2D-Shear Wave Elastography in Ruling Out the Presence of High-Risk Varices in Cirrhotic Patients. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 2653-2660	4	17
318	Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 1327-1340	5.6	12
317	Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 1040-1049	3.4	1
316	Can we stop nucleoside analogues before HBsAg loss?. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 936-941	3.4	11
315	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , <b>2019</b> , 19, 275-286	25.5	57
314	A hepatitis C outbreak preceded the HIV outbreak among persons who inject drugs in Athens, Greece: Insights from a mathematical modelling study. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 1311-1317	3.4	6
313	Aiming towards hepatitis C virus elimination in Greece. <i>Annals of Gastroenterology</i> , <b>2019</b> , 32, 321-329	2.2	5
312	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , <b>2019</b> , 71, 1070	11.2	23
311	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1625-1633.e1	6.9	56
310	Long-term Effects of Treatment for Chronic HBV Infection on Patient-Reported Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1641-1642.e1	6.9	7



309	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 54-64.e1	6.9	31
308	Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis. <i>Annals of Gastroenterology</i> , <b>2019</b> , 32, 1-23	2.2	25
307	Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25 Suppl 1, 6-17	3.4	45
306	Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. <i>Metabolism: Clinical and Experimental</i> , <b>2018</b> , 83, 120-127	12.7	33
305	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 1129-1136	13.4	64
304	Hepatitis B: Who and when to treat?. <i>Liver International</i> , <b>2018</b> , 38 Suppl 1, 71-78	7.9	15
303	Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in noncirrhotic HBeAg-negative chronic hepatitis B patients: Results from the DARING-B prospective Greek study. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S88-S89	13.4	3
302	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 383-403	18.8	702
301	Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , <b>2018</b> , 68, 415-424	11.2	32
300	A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 547-555	6.1	21
299	DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 677-685	1.6	43
298	Impact of Interferon- $\beta$ Receptor-1 Promoter Polymorphisms on the Transcriptome of the Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 777	8.4	6
297	Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 3487-3497	4	28
296	Metastatic Signet-Ring Cell Carcinoma of the Skin. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1427-7		2
295	A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B. <i>Annals of Gastroenterology</i> , <b>2018</b> , 31, 712-721	2.2	3
294	Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis. <i>Annals of Gastroenterology</i> , <b>2018</b> , 31, 598-603	2.2	2
293	The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25 Suppl 3, 6-14	3.4	21
292	Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues. <i>Annals of Gastroenterology</i> , <b>2018</b> , 31, 365-370	2.2	6

291	Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. <i>Annals of Gastroenterology</i> , <b>2018</b> , 31, 480-490	2.2	27
290	Evaluation of portal hypertension in the cirrhotic patient: hepatic vein pressure gradient and beyond. <i>Scandinavian Journal of Gastroenterology</i> , <b>2018</b> , 53, 1153-1164	2.4	16
289	Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. <i>British Journal of Nutrition</i> , <b>2018</b> , 120, 164-175	3.6	48
288	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 161-176	18.8	1196
287	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 370-398	13.4	2354
286	Treatment of chronic hepatitis C with direct-acting antivirals in patients with ðhalassaemia major and advanced liver disease. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 130-136	4.5	15
285	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , <b>2017</b> , 66, 1444-1453	11.2	180
284	Adherence to follow-up and treatment recommendations in Greek and immigrant patients with chronic hepatitis B in Greece. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2017</b> , 29, 264-270	2.2	3
283	Proton pump inhibitor and selective serotonin reuptake inhibitor therapy for the management of noncardiac chest pain. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2017</b> , 29, 1054-1058	2.2	2
282	Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy. <i>Cancer Investigation</i> , <b>2017</b> , 35, 443-455	2.1	44
281	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 325-336	18.8	153
280	Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B. <i>Liver International</i> , <b>2017</b> , 37, 1642-1650	7.9	9
279	Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. <i>Metabolism: Clinical and Experimental</i> , <b>2017</b> , 68, 119-132	12.7	135
278	Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1448-1455	59.2	277
277	Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation. <i>World Journal of Hepatology</i> , <b>2017</b> , 9, 180-190	3.4	11
276	DARING-B: discontinuation of effective entecavir or tenofovir therapy in non-cirrhotic HBeAg-negative chronic hepatitis B patients: a prospective Greek study. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S26	13.4	20
275	Validation of the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease: an individual patient meta-analysis. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S69	13.4	2
274	Treatment cascade of hepatitis B and C in general, migrant and Roma populations. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S71-S72	13.4	2



273	Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2017</b> , 29, 56-60	2.2	4
272	A "healthy diet-optimal sleep" lifestyle pattern is inversely associated with liver stiffness and insulin resistance in patients with nonalcoholic fatty liver disease. <i>Applied Physiology, Nutrition and Metabolism</i> , <b>2017</b> , 42, 250-256	3	15
271	Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 466-472	4	10
270	Associations Between Lifestyle Characteristics and the Presence of Nonalcoholic Fatty Liver Disease: A Case-Control Study. <i>Metabolic Syndrome and Related Disorders</i> , <b>2017</b> , 15, 72-79	2.6	25
269	Intestinal Bacteria Composition and Translocation of Bacteria in Inflammatory Bowel Disease. <i>PLoS ONE</i> , <b>2017</b> , 12, e0170034	3.7	73
268	Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease. <i>Annals of Gastroenterology</i> , <b>2017</b> , 30, 209-216	2.2	2
267	Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. <i>Annals of Gastroenterology</i> , <b>2017</b> , 30, 327-343	2.2	5
266	Comparative Study of Mutations in Single Nucleotide Polymorphism Loci of and Genes in Patients Who Underwent Screening Colonoscopy, With and Without Premalignant Intestinal Polyps. <i>Anticancer Research</i> , <b>2017</b> , 37, 651-657	2.3	13
265	Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 7387-7396	5.6	45
264	Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice. <i>Annals of Gastroenterology</i> , <b>2017</b> , 30, 542-549	2.2	2
263	Hippocratic views in the treatment of rectal prolapse. <i>Acta Gastro-Enterologica Belgica</i> , <b>2017</b> , 80, 411-415.6		
262	Combination of Tenofovir Disoproxil Fumarate and Peginterferon α2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , <b>2016</b> , 150, 134-144.e10	13.3	219
261	Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2016</b> , 1, 25-35	18.8	38
260	Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1471-1477	3.3	35
259	Case 21-2016: A Man in an Unresponsive State. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1697	59.2	
258	Reliability and applicability of two-dimensional shear-wave elastography for the evaluation of liver stiffness. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 28, 1204-9	2.2	18
257	Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23 Suppl 1, 1-12	3.4	21
256	PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 800-6	13.4	227

255	Changes in serum transforming growth factor- $\beta$ levels in chronic hepatitis C patients under antiviral therapy. <i>Annals of Gastroenterology</i> , <b>2016</b> , 29, 79-84	2.2	11
254	The significance of platelet microparticles in patients with chronic hepatitis C and their association with antiviral treatment and smoking. <i>Annals of Gastroenterology</i> , <b>2016</b> , 29, 201-7	2.2	5
253	The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. <i>Clinical and Molecular Hepatology</i> , <b>2016</b> , 22, 319-326	6.9	50
252	Elevated Serum Levels of the Antiapoptotic Protein Decoy-Receptor 3 Are Associated with Advanced Liver Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 2016, 2637010	2.8	5
251	Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. <i>Hepatology</i> , <b>2016</b> , 63, 1481-92.2	92.2	153
250	Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population. <i>Pharmacological Reports</i> , <b>2016</b> , 68, 476-82	3.9	4
249	Rg-101 in Combination With 4 Weeks of Oral Direct Acting Antiviral Therapy Achieves High Virologic Response Rates in Treatment Naïve Genotype 1 and 4 Chronic Hepatitis C Patients: Interim Results from a Randomised, Multicenter, Phase 2 Study. <i>Journal of Hepatology</i> , <b>2016</b> , 64, S159	13.4	5
248	A Genotype-Specific Baseline Score to Predict Response at 48 Weeks Post-Treatment to Peginterferon Alfa-2a in Patients with HBeAg-Negative Chronic Hepatitis B. <i>Journal of Hepatology</i> , <b>2016</b> , 64, S599-S600	13.4	3
247	Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 957-966	6.1	28
246	HBV: Do I treat my immunotolerant patients?. <i>Liver International</i> , <b>2016</b> , 36 Suppl 1, 93-9	7.9	15
245	Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the UK: systematic review and economic evaluation. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23, 139-49	3.4	14
244	O117 : Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB). <i>Journal of Hepatology</i> , <b>2015</b> , 62, S251-S252	13.4	10
243	P0641 : Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC). <i>Journal of Hepatology</i> , <b>2015</b> , 62, S559-S560	13.4	4
242	Optimal management of hepatitis B virus infection - EASL Special Conference. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 1238-53	13.4	81
241	Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 120-7	3.4	34
240	Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 409-15	3.4	21
239	Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?. <i>Liver International</i> , <b>2015</b> , 35 Suppl 1, 100-6	7.9	11
238	On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. <i>Liver International</i> , <b>2015</b> , 35, 1540-8	7.9	24

237	Associations between dietary intake and the presence of the metabolic syndrome in patients with non-alcoholic fatty liver disease. <i>Journal of Human Nutrition and Dietetics</i> , <b>2015</b> , 28, 409-15	3.1	22
236	Controversial Issues in Current Treatment of Chronic HBV Infection. <i>Current Hepatology Reports</i> , <b>2015</b> , 14, 164-170	1	
235	Recent advances in cirrhotic cardiomyopathy. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 1141-51	4	20
234	The interferon receptor-1 promoter polymorphisms affect the outcome of Caucasians with HBeAg-negative chronic HBV infection. <i>Liver International</i> , <b>2015</b> , 35, 2506-13	7.9	8
233	Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 1079-87	3.4	16
232	Increased abdominal fat levels measured by bioelectrical impedance are associated with histological lesions of nonalcoholic steatohepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2015</b> , 27, 907-13	2.2	7
231	Blood redox status is associated with the likelihood of nonalcoholic fatty liver disease irrespectively of diet & total antioxidant capacity. <i>Nutrition Research</i> , <b>2015</b> , 35, 41-8	4	18
230	Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 956-67	13.4	285
229	Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22 Suppl 1, 6-25	3.4	82
228	Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22 Suppl 1, 46-73	3.4	37
227	Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 363-70	13.4	124
226	The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22 Suppl 1, 26-45	3.4	100
225	The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis. <i>Annals of Gastroenterology</i> , <b>2015</b> , 28, 109-117	2.2	14
224	Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience. <i>Annals of Gastroenterology</i> , <b>2015</b> , 28, 481-6	2.2	2
223	Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 9526-33	5.6	22
222	The impact of cereal grain consumption on the development and severity of non-alcoholic fatty liver disease. <i>European Journal of Nutrition</i> , <b>2014</b> , 53, 1727-35	5.2	28
221	Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 62-8	13.4	45
220	Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. <i>Clinical Nutrition</i> , <b>2014</b> , 33, 678-83	5.9	135

219	P1075 PAGE-B: RISK SCORE FOR HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS RECEIVING ENTECAVIR (ETV) OR TENOFOVIR (TDF). <i>Journal of Hepatology</i> , <b>2014</b> , 60, S435	13.4	9
218	Four years of tenofovir monotherapy for NUC na $\bar{u}$ e field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, e14	3.3	4
217	The usefulness of transient elastography in the assessment of patients with HBeAg-negative chronic hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 517-24	3.4	11
216	Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 624-32	3.4	5
215	HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?. <i>Liver International</i> , <b>2014</b> , 34 Suppl 1, 127-32	7.9	10
214	Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. <i>Liver International</i> , <b>2014</b> , 34, 1452-63	7.9	45
213	Liver function breath tests for differentiation of steatohepatitis from simple fatty liver in patients with nonalcoholic Fatty liver disease. <i>Journal of Clinical Gastroenterology</i> , <b>2014</b> , 48, 59-65	3	6
212	Endoscopic and histological findings and Helicobacter pylori status in patients with reflux and/or dyspeptic symptoms: a recent Greek cohort study. <i>Gastroenterology Nursing</i> , <b>2014</b> , 37, 431-8	1	3
211	Telbivudine improves renal function in patients with chronic hepatitis B. <i>Gastroenterology</i> , <b>2014</b> , 146, 138-146.e5	13.3	90
210	O4 PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON- $\alpha$ PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDV RNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY. <i>Journal of Hepatology</i> , <b>2014</b> , 60, S2-S3	13.4	37
209	Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 35-46	6.1	46
208	Anti-HDV IgM as a marker of disease activity in hepatitis delta. <i>PLoS ONE</i> , <b>2014</b> , 9, e101002	3.7	31
207	Significance of the C-caffeine breath test for patients with cirrhosis. <i>Annals of Gastroenterology</i> , <b>2014</b> , 27, 53-59	2.2	3
206	Sofosbuvir: a novel oral agent for chronic hepatitis C. <i>Annals of Gastroenterology</i> , <b>2014</b> , 27, 331-337	2.2	56
205	Hepatitis B virus treatment: Which patients can have treatment deferred?. <i>Clinical Liver Disease</i> , <b>2013</b> , 2, 15-17	2.2	6
204	766 HEPATOCELLULAR CARCINOMA (HCC) RISK IN HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBe $\bar{u}$ ) WITH OR WITHOUT CIRRHOSIS TREATED WITH ENTECAVIR: RESULTS OF THE NATIONWIDE HepNet.Greece COHORT STUDY. <i>Journal of Hepatology</i> , <b>2013</b> , 58, S312	13.4	3
203	High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. <i>American Journal of Transplantation</i> , <b>2013</b> , 13, 353-62	8.7	104
202	Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?. <i>Liver International</i> , <b>2013</b> , 33 Suppl 1, 151-6	7.9	13

201	Treatment of hepatitis B in patients with chronic kidney disease. <i>Kidney International</i> , <b>2013</b> , 84, 880-5	9.9	28
200	Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 949-56	13.4	75
199	Ultrasensitive amplification refractory mutation system real-time PCR (ARMS RT-PCR) assay for detection of minority hepatitis B virus-resistant strains in the era of personalized medicine. <i>Journal of Clinical Microbiology</i> , <b>2013</b> , 51, 2893-900	9.7	11
198	Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, e37-46	3.4	66
197	Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2013</b> , 25, 587-93	2.2	9
196	Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 8822-30	5.6	31
195	Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 9189-97	5.6	24
194	The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease. <i>Journal of Clinical Gastroenterology</i> , <b>2013</b> , 47, 280-6	3	28
193	525 TENOFOVIR MONOTHERAPY FOR NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE IN 302 PATIENTS FOLLOWED FOR 30 MONTHS. <i>Journal of Hepatology</i> , <b>2012</b> , 56, S208	13.4	3
192	Significance of liver histology in HBsAg-positive, IgM anti-HBc-negative acute hepatitis B virus-related hepatitis. <i>Histopathology</i> , <b>2012</b> , 61, 881-8	7.3	1
191	Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis. <i>Transplant International</i> , <b>2012</b> , 25, 1174-81	3	28
190	1354 HEPATITIS C VIRUS REINFECTION FOLLOWING SUSTAINED VIROLOGICAL RESPONSE IN INTRAVENOUS DRUG USERS. <i>Journal of Hepatology</i> , <b>2012</b> , 56, S532	13.4	2
189	Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 196-202	13.4	127
188	EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 167-85	13.4	2480
187	Letter: renal tubular dysfunction during nucleotide analogue therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 992-3; author reply 993	6.1	2
186	Public health issues of hepatitis C virus infection. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2012</b> , 26, 371-80	2.5	21
185	Variability in the management of nonvariceal upper gastrointestinal bleeding in Europe: an observational study. <i>Advances in Therapy</i> , <b>2012</b> , 29, 1026-36	4.1	13
184	The safety of anti-TNF therapy in patients with hepatitis B and C virus infection. <i>International Journal of Clinical Rheumatology</i> , <b>2012</b> , 7, 191-196	1.5	1



183	Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. <i>Annals of Gastroenterology</i> , <b>2012</b> , 25, 45-51	2.2	47
182	Greek results of the "ENERGIB" European study on non-variceal upper gastrointestinal bleeding. <i>Annals of Gastroenterology</i> , <b>2012</b> , 25, 327-332	2.2	
181	Current progress in the treatment of chronic hepatitis C. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 6060-9	5.6	23
180	Elastography for hepatic fibrosis severity in chronic hepatitis B or C. <i>Case Reports in Gastroenterology</i> , <b>2011</b> , 5, 63-72	1	2
179	Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 61-8	13.4	58
178	350 TRANSIENT ELASTOGRAPHY (FIBROSCAN) IN PATIENTS WITH CHRONIC HEPATITIS B IN EVERYDAY CLINICAL PRACTICE. <i>Journal of Hepatology</i> , <b>2011</b> , 54, S140-S141	13.4	2
177	714 HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT. <i>Journal of Hepatology</i> , <b>2011</b> , 54, S286-S287	13.4	3
176	852 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) MAY DEVELOP IN PATIENTS WITH NORMAL BODY MASS INDEX (BMI). <i>Journal of Hepatology</i> , <b>2011</b> , 54, S340	13.4	2
175	Is there any progress in the treatment of non-alcoholic fatty liver disease?. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , <b>2011</b> , 2, 1-5	3	11
174	Entecavir treatment in HBV-related decompensated cirrhosis. <i>Future Virology</i> , <b>2011</b> , 6, 1275-1281	2.4	
173	Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 505-14	1.6	4
172	Clinical predictors of poor outcomes among patients with nonvariceal upper gastrointestinal bleeding in Europe. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 1225-33	6.1	40
171	Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. <i>Liver International</i> , <b>2011</b> , 31 Suppl 1, 95-103	7.9	11
170	Left ventricle enlargement and increased systolic velocity in the mitral valve are indirect markers of the hepatopulmonary syndrome. <i>Liver International</i> , <b>2011</b> , 31, 1388-94	7.9	17
169	Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. <i>Liver International</i> , <b>2011</b> , 31, 1525-32	7.9	12
168	Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. <i>Liver Transplantation</i> , <b>2011</b> , 17, 1176-90	4.5	96
167	Effect of antiviral therapy on the immunohistochemical expression of bcl-xL and bax protein in patients with HBeAg-negative chronic hepatitis B. <i>Journal of Medical Virology</i> , <b>2011</b> , 83, 1165-71	19.7	
166	Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. <i>Hepatology</i> , <b>2011</b> , 53, 62-72	11.2	242



165	Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. <i>Gut</i> , <b>2011</b> , 60, 1109-16	19.2	137
164	Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. <i>Liver International</i> , <b>2010</b> , 30, 1454-60	7.9	24
163	Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 800-6	3.4	40
162	Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. <i>American Journal of Hypertension</i> , <b>2010</b> , 23, 1183-9	2.3	89
161	Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1352-5	2.4	104
160	CagA and VacA polymorphisms are associated with distinct pathological features in Helicobacter pylori-infected adults with peptic ulcer and non-peptic ulcer disease. <i>Journal of Clinical Microbiology</i> , <b>2010</b> , 48, 2237-9	9.7	24
159	Liver grafts from anti-hepatitis B core positive donors: a systematic review. <i>Journal of Hepatology</i> , <b>2010</b> , 52, 272-9	13.4	209
158	Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 348-56	13.4	336
157	A Greek survey of community prevalence and characteristics of constipation. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 354-60	2.2	25
156	Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. <i>Journal of Clinical Gastroenterology</i> , <b>2010</b> , 44, e87-95	3	35
155	The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 172-9	2.2	15
154	Patient management and clinical decision making in HBV--aims of therapy and what we can achieve. <i>Antiviral Therapy</i> , <b>2010</b> , 15 Suppl 3, 45-51	1.6	2
153	Survivin expression in colorectal carcinomas: correlations with clinicopathological parameters and survival. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 2958-64	4	12
152	Serum markers of hepatocyte apoptosis: current terminology and predictability in clinical practice. <i>Hepatology</i> , <b>2010</b> , 51, 717-8	11.2	5
151	Smoking is associated with histological severity in nonalcoholic steatohepatitis. <i>Hepatology</i> , <b>2010</b> , 52, 1522-3	11.2	7
150	Management of HBV Infection and Liver Transplantation <b>2010</b> , 748-761		1
149	A novel immunological assay for hepcidin quantification in human serum. <i>PLoS ONE</i> , <b>2009</b> , 4, e4581	3.7	62
148	Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. <i>Mediators of Inflammation</i> , <b>2009</b> , 2009, 831670	4.3	87

147	Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. <i>Scandinavian Journal of Gastroenterology</i> , <b>2009</b> , 44, 6-14	2.4	48
146	Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology. <i>Journal of Clinical Microbiology</i> , <b>2009</b> , 47, 2544-50	9.7	18
145	Reply:. <i>Hepatology</i> , <b>2009</b> , 49, 705-706	11.2	2
144	Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 29, 1121-30	6.1	18
143	Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 947-54	6.1	17
142	Epidemiology, course and disease burden of chronic hepatitis B virus infection. HEPNET study for chronic hepatitis B: a multicentre Greek study. <i>Journal of Viral Hepatitis</i> , <b>2009</b> , 16, 195-202	3.4	27
141	Prevalence of glucose intolerance in patients with chronic hepatitis B or C: a prospective case-control study. <i>Journal of Viral Hepatitis</i> , <b>2009</b> , 16, 430-6	3.4	11
140	Current management of hepatitis B virus infection before and after liver transplantation. <i>Liver International</i> , <b>2009</b> , 29, 1294-305	7.9	58
139	EASL clinical practice guidelines on the management of chronic hepatitis B: the need for liver biopsy. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 226-7	13.4	22
138	Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 468-74	13.4	72
137	Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 931-8	13.4	37
136	2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. <i>Gastroenterology</i> , <b>2009</b> , 136, 486-95	13.3	470
135	Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B. <i>Scandinavian Journal of Gastroenterology</i> , <b>2009</b> , 44, 752-9	2.4	40
134	230 SERUM HEPCIDIN LEVELS DEPEND ON AETIOLOGY BUT NOT SEVERITY OF CIRRHOSIS. <i>Journal of Hepatology</i> , <b>2009</b> , 50, S93	13.4	3
133	911 PROLONGED EFFICACY AND SAFETY OF 3 YEARS OF CONTINUOUS TELBIVUDINE TREATMENT IN POOLED DATA FROM GLOBE AND 015 STUDIES IN CHRONIC HEPATITIS B PATIENTS. <i>Journal of Hepatology</i> , <b>2009</b> , 50, S331	13.4	14
132	Role of genetic polymorphisms in the progression of liver fibrosis in chronic hepatitis C virus infection. <i>Liver International</i> , <b>2008</b> , 28, 764-6	7.9	3
131	Clinicopathological features and natural history of acute sporadic non-(A-E) hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2008</b> , 23, 1208-15	4	6
130	Review article: novel therapeutic options for chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 27, 866-84	6.1	18

129	Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , <b>2008</b> , 15, 434-41	3.4	63
128	Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. <i>Gynecologic Oncology</i> , <b>2008</b> , 108, 421-7	4.9	71
127	Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. <i>Scandinavian Journal of Gastroenterology</i> , <b>2008</b> , 43, 1128-36	2.4	70
126	Changes of liver and muscle enzymes activity in patients with rigor. <i>European Journal of Internal Medicine</i> , <b>2008</b> , 19, 109-14	3.9	
125	Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. <i>Lancet Infectious Diseases</i> , <b>2008</b> , 8, 167-78	25.5	162
124	Ethics related to liver biopsies and antiviral therapies in chronic viral hepatitis. <i>Digestive Diseases</i> , <b>2008</b> , 26, 59-65	3.2	3
123	Resistance issues in treating chronic hepatitis B. <i>Future Microbiology</i> , <b>2008</b> , 3, 525-38	2.9	18
122	Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2008</b> , 20, 5-9	2.2	45
121	Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. <i>Gut</i> , <b>2008</b> , 57, 500-6	19.2	36
120	Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 27, 80-9	6.1	56
119	Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 27, 266-73	6.1	34
118	Potential role of apoptosis and apoptotic regulatory proteins in colorectal neoplasia: correlations with clinico-pathological parameters and survival. <i>Digestive Diseases and Sciences</i> , <b>2008</b> , 53, 451-60	4	5
117	Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. <i>Liver Transplantation</i> , <b>2008</b> , 14, 138-43	4.5	140
116	Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?. <i>Hepatology</i> , <b>2008</b> , 48, 1451-9	11.2	95
115	Prophylactic and therapeutic use of recombinant activated factor VII in patients with cirrhosis and coagulation impairment. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39, 490-4	3.3	8
114	Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39, 936-42	3.3	37
113	Serum hepatitis B virus-DNA cutoff levels in hepatitis B e antigen-negative chronic hepatitis B virus infection. <i>Hepatology</i> , <b>2007</b> , 46, 606-7; author reply 607	11.2	5
112	Adipokines and insulin resistance in chronic hepatitis C. <i>Hepatology</i> , <b>2007</b> , 46, 2050-1; author reply 2051	11.2	2

111	Combined HLA-DR and -DQ disparity is associated with a stable course of ulcerative colitis after liver transplantation for primary sclerosing cholangitis. <i>Liver Transplantation</i> , <b>2007</b> , 13, 552-7	4.5	20
110	Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load. <i>Vox Sanguinis</i> , <b>2007</b> , 92, 8-14	3.1	19
109	Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. <i>Gynecologic Oncology</i> , <b>2007</b> , 106, 75-81	4.9	58
108	Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 634-41	0.7	32
107	Response to the article: McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. <i>Am J Gastroenterol</i> 2006; 101:812-22. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 201-2	0.7	16
106	First appearance of Crohn's disease following infliximab treatment for spondylarthropathy. <i>Scandinavian Journal of Gastroenterology</i> , <b>2007</b> , 42, 784-5	2.4	6
105	Strategy to characterize the number and type of repeating EPIYA phosphorylation motifs in the carboxyl terminus of CagA protein in Helicobacter pylori clinical isolates. <i>Journal of Clinical Microbiology</i> , <b>2007</b> , 45, 488-95	9.7	56
104	High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2007</b> , 19, 281-7	2.2	42
103	[481] HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBe-) IN CHRONIC HBV PATIENTS WITH SERUM HBV-DNA LEVELS BELOW 2,000 IU/mL. <i>Journal of Hepatology</i> , <b>2007</b> , 46, S183	13.4	2
102	[644] HEPATIC STEATOSIS PREDICTS OUTCOME OF CHRONIC HEPATITIS C THERAPY WITH PEG-INTERFERON PLUS RIBAVIRIN, INDEPENDENTLY OF GENOTYPE OR BMI BUT IN CORRELATION TO INSULIN RESISTANCE (HOMA-IR). <i>Journal of Hepatology</i> , <b>2007</b> , 46, S243	13.4	5
101	The Bcl-2/Bax system and apoptosis in ulcerative colitis. <i>Hepato-Gastroenterology</i> , <b>2007</b> , 54, 1085-8		7
100	Quantitative Analysis of Hepatitis D Virus RNA and Hepatitis B Surface Antigen Serum Levels in Chronic Delta Hepatitis Improves Treatment Monitoring. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 381-388	1.6	42
99	Pseudohyperkalemia in serum: the phenomenon and its clinical magnitude. <i>Translational Research</i> , <b>2006</b> , 147, 139-44		50
98	Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. <i>Seminars in Liver Disease</i> , <b>2006</b> , 26, 130-41	7.3	191
97	An evaluation of emergency sclerotherapy of varices in randomized trials: looking the needle in the eye. <i>Endoscopy</i> , <b>2006</b> , 38, 797-807	3.4	36
96	Simultaneous diagnosis of ulcerative jejunoileitis and coeliac disease in an elderly man. <i>Digestion</i> , <b>2006</b> , 73, 20-4	3.6	6
95	Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. <i>Clinical Gastroenterology and Hepatology</i> , <b>2006</b> , 4, 130-42	6.9	97
94	The evolving role of leptin and adiponectin in chronic liver diseases. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 2629-40	0.7	145

93	Hepatocellular carcinoma presenting with pleuritic pain. <i>European Journal of Internal Medicine</i> , <b>2006</b> , 17, 222	3.9	1
92	Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2006</b> , 18, 389-96	2.2	42
91	Hepatobiliary and pancreatic: spontaneous splenorenal shunts in portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2006</b> , 21, 1214	4	1
90	Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. <i>Journal of Viral Hepatitis</i> , <b>2006</b> , 13, 303-10	3.4	80
89	A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23, 99-106	6.1	21
88	Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2006</b> , 21, 581-7	4	20
87	Desmoid tumor presenting as intra-abdominal abscess. <i>Digestive Diseases and Sciences</i> , <b>2006</b> , 51, 68-9	4	17
86	Drug evaluation: LB-80380--a novel phosphonate nucleoside for the potential treatment of HBV infection. <i>Current Opinion in Molecular Therapeutics</i> , <b>2006</b> , 8, 352-7		1
85	Prevalence and impact of upper and lower gastrointestinal symptoms in the Greek urban general population. <i>Scandinavian Journal of Gastroenterology</i> , <b>2005</b> , 40, 412-21	2.4	31
84	Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis. <i>Liver International</i> , <b>2005</b> , 25, 57-61	7.9	50
83	Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2005</b> , 12, 199-206	3.4	29
82	Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. <i>Journal of Viral Hepatitis</i> , <b>2005</b> , 12, 543-50	3.4	26
81	Systematic review: The model for end-stage liver disease--should it replace Child-PughB classification for assessing prognosis in cirrhosis?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 22, 1079-89	6.1	287
80	Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. <i>Hepatology</i> , <b>2005</b> , 42, 121-9	11.2	193
79	Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. <i>Liver Transplantation</i> , <b>2005</b> , 11, 386-95	4.5	85
78	MELD vs Child-Pugh and creatinine-modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 3099-104	5.6	70
77	Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 3811-6	5.6	19
76	Pericarditis and possible antiphospholipid syndrome on primary biliary cirrhosis. <i>Annals of Hepatology</i> , <b>2004</b> , 3, 167-168	3.1	4

75	Emerging treatments in chronic hepatitis B. <i>Expert Opinion on Emerging Drugs</i> , <b>2004</b> , 9, 207-21	3.7	12
74	Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options. <i>Journal of Viral Hepatitis</i> , <b>2004</b> , 11, 287-96	3.4	15
73	Recent peginterferon and ribavirin combination trials. <i>Current Hepatitis Reports</i> , <b>2004</b> , 3, 30-37		4
72	Review article: current management of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 19, 25-37	6.1	53
71	Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. <i>Expert Review of Anti-Infective Therapy</i> , <b>2004</b> , 2, 475-83	5.5	19
70	Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. <i>American Journal of Medicine</i> , <b>2004</b> , 116, 601-5	2.4	20
69	Naftidrofuryl-induced liver injury. <i>American Journal of Gastroenterology</i> , <b>2003</b> , 98, 1448-50	0.7	5
68	Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. <i>American Journal of Gastroenterology</i> , <b>2003</b> , 98, 2261-7	0.7	78
67	Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. <i>Gut</i> , <b>2003</b> , 52, 404-9	19.2	85
66	Treatment of HBeAg-negative chronic hepatitis B. <i>Seminars in Liver Disease</i> , <b>2003</b> , 23, 81-8	7.3	60
65	Recommendations of the ESGE workshop on Informed Consent for Digestive Endoscopy. First European Symposium on Ethics in Gastroenterology and Digestive Endoscopy, Kos, Greece, June 2003. <i>Endoscopy</i> , <b>2003</b> , 35, 772-4	3.4	9
64	Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. <i>Transplantation</i> , <b>2003</b> , 75, 186-90	1.8	66
63	Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. <i>American Journal of Transplantation</i> , <b>2003</b> , 3, 250-8	8.7	59
62	Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. <i>American Journal of Gastroenterology</i> , <b>2003</b> , 98, 2261-2267	0.7	6
61	Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , <b>2003</b> , 4, 541-51	4.1	11
60	Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others). <i>Journal of Hepatology</i> , <b>2003</b> , 39 Suppl 1, S172-6	13.4	8
59	Ursodeoxycholic acid and histological progression in primary biliary cirrhosis. <i>Journal of Hepatology</i> , <b>2003</b> , 39, 1094-5	13.4	10
58	Peginterferon-2a (40kDa) for chronic hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , <b>2003</b> , 4, 541-551	4	20



57	Precore mutant chronic hepatitis B - approach to management. <i>MedGenMed: Medscape General Medicine</i> , <b>2003</b> , 5, 1		2
56	Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. <i>Hepatology</i> , <b>2002</b> , 36, 219-26	11.2	158
55	Mesenteric venous thrombosis after transcatheter arterial chemoembolization for hepatocellular carcinoma. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 2685-6	0.7	
54	Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 2063-70	0.7	47
53	Primary aortojejunal fistula due to foreign body: a rare cause of gastrointestinal bleeding. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2002</b> , 14, 797-800	2.2	16
52	Serum HBV-DNA levels in inactive hepatitis B virus carriers. <i>Gastroenterology</i> , <b>2002</b> , 122, 2092-3; author reply 2093	13.3	36
51	Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 1618-28	0.7	99
50	Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2001</b> , 15, 689-98	6.1	100
49	Management of recurrent hepatitis C after liver transplantation. <i>Journal of Viral Hepatitis</i> , <b>2001</b> , 8, 159-68	3.4	19
48	Diagnosis and management of pre-core mutant chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2001</b> , 8, 311-21	3.4	76
47	A simulation modelling approach to evaluating alternative policies for the management of the waiting list for liver transplantation. <i>Health Care Management Science</i> , <b>2001</b> , 4, 117-24	4	35
46	Acute pancreatitis associated with Salmonella enteritidis. <i>American Journal of Gastroenterology</i> , <b>2001</b> , 96, 3450-1	0.7	5
45	The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2001</b> , 34, 306-13	13.4	250
44	Course of virologic breakthroughs under lamivudine therapy in patients with precore mutant HBV related liver disease. <i>Gastroenterology</i> , <b>2001</b> , 120, A385	13.3	2
43	Significance of HBV viremia levels estimated by a quantitative PCR assay in the evaluation of HBeAg negative chronic HBV infection. <i>Journal of Hepatology</i> , <b>2001</b> , 34, 115	13.4	2
42	The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. <i>Transplantation</i> , <b>2001</b> , 72, 412-8	1.8	79
41	Recurrent hepatitis C after liver transplantation. <i>Journal of Medical Virology</i> , <b>2000</b> , 61, 443-54	19.7	24
40	Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. <i>Hepatology</i> , <b>2000</b> , 32, 847-51	11.2	279

39	Ursodeoxycholic-acid for primary biliary cirrhosis: Final results of A12-year prospective, randomised, controlled trial. <i>Journal of Hepatology</i> , <b>2000</b> , 32, 40	13.4	6
38	Efficacy of long term lamivudine therapy in HBeAg negative chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2000</b> , 32, 98	13.4	113
37	Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens. <i>Gut</i> , <b>1999</b> , 45, 427-34	19.2	56
36	Transjugular liver biopsy in the 1990s: a 2-year audit. <i>Alimentary Pharmacology and Therapeutics</i> , <b>1999</b> , 13, 603-8	6.1	55
35	Infection and hemostasis in decompensated cirrhosis: a prospective study using thrombelastography. <i>Hepatology</i> , <b>1999</b> , 29, 1085-90	11.2	68
34	Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. <i>Hepatology</i> , <b>1999</b> , 30, 612-22	11.2	278
33	The outcome of hepatitis C virus infection after liver transplantation—is it influenced by the type of immunosuppression?. <i>Journal of Hepatology</i> , <b>1999</b> , 30, 731-8	13.4	29
32	Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis. <i>Journal of Hepatology</i> , <b>1999</b> , 31, 747-50	13.4	49
31	p53 protein accumulation and colonic adenoma recurrence. <i>European Journal of Gastroenterology and Hepatology</i> , <b>1999</b> , 11, 547-52	2.2	2
30	Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. <i>Transplantation</i> , <b>1999</b> , 68, 155-7	1.8	56
29	Long-term outcome of chronic hepatitis C treated with interferon. <i>Italian Journal of Gastroenterology and Hepatology</i> , <b>1999</b> , 31, 459-61		
28	Liver transplantation and inflammatory bowel disease. <i>Journal of Hepatology</i> , <b>1998</b> , 28, 1070-6	13.4	15
27	Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. <i>Gut</i> , <b>1998</b> , 43, 639-44	19.2	147
26	p53 and bcl-2 protein expression in rectosigmoid adenomas. <i>American Journal of Gastroenterology</i> , <b>1998</b> , 93, 1136-40	0.7	3
25	Indefinite dysplasia in ulcerative colitis has little clinical significance and is not associated with p53 protein accumulation. <i>American Journal of Gastroenterology</i> , <b>1998</b> , 93, 285-6	0.7	2
24	Factors associated with severity and disease progression in chronic hepatitis C. <i>Hepato-Gastroenterology</i> , <b>1998</b> , 45, 1678-83		7
23	Differential diagnosis of acute HBsAg positive hepatitis using IgM anti-HBc by a rapid, fully automated microparticle enzyme immunoassay. <i>Journal of Hepatology</i> , <b>1997</b> , 26, 14-9	13.4	20
22	Significance of IgM anti-HCV core level in chronic hepatitis C. <i>Journal of Hepatology</i> , <b>1997</b> , 27, 36-41	13.4	15

21	Predictors of the early development of advanced metachronous colon adenomas. <i>Hepato-Gastroenterology</i> , <b>1997</b> , 44, 533-8		3
20	Seasonal variation in exacerbations of ulcerative colitis. <i>Hepato-Gastroenterology</i> , <b>1997</b> , 44, 1334-8		5
19	Histopathology of chronic hepatitis C in relation to epidemiological factors. <i>Journal of Hepatology</i> , <b>1996</b> , 24, 27-32	13.4	50
18	Terbinafine-induced cholestatic liver disease. <i>Journal of Hepatology</i> , <b>1996</b> , 24, 753-6	13.4	41
17	Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. <i>European Journal of Gastroenterology and Hepatology</i> , <b>1996</b> , 8, 1083-8	2.2	13
16	Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. <i>American Journal of Gastroenterology</i> , <b>1996</b> , 91, 1734-8	0.7	14
15	Characteristics of rectosigmoid adenomas as predictors of synchronous advanced proximal colon neoplasms. <i>American Journal of Gastroenterology</i> , <b>1996</b> , 91, 1809-13	0.7	16
14	Biochemical and virological response of chronic hepatitis C after treatment with interferon-alpha for 6 or 12 months: predictors of sustained remission. <i>European Journal of Gastroenterology and Hepatology</i> , <b>1996</b> , 8, 469-75	2.2	4
13	Amineptine induced liver injury. Report of two cases and brief review of the literature. <i>Hepato-Gastroenterology</i> , <b>1996</b> , 43, 1015-9		1
12	Hepatitis E virus infection in a cohort of patients with acute non-A, non-B hepatitis. <i>Journal of Hepatology</i> , <b>1995</b> , 23, 668-73	13.4	28
11	Fulminant hepatitis due to Epstein-Barr virus infection. <i>Journal of Hepatology</i> , <b>1995</b> , 23, 348-350	13.4	37
10	Fulminant hepatitis due to Epstein-Barr virus infection. <i>Journal of Hepatology</i> , <b>1995</b> , 23, 348-50	13.4	9
9	Early prediction of successful alpha-interferon therapy of chronic hepatitis C by core-IgM antibodies to hepatitis C virus. <i>Journal of Hepatology</i> , <b>1994</b> , 20, 305-6	13.4	18
8	Prevalence of antibodies to hepatitis C virus in Greek patients with chronic liver disease. <i>Journal of Hepatology</i> , <b>1994</b> , 20, 311	13.4	3
7	Prevalence of antibodies to hepatitis C virus in Greek patients with chronic liver disease. <i>Journal of Hepatology</i> , <b>1994</b> , 20, 843	13.4	
6	The role of hepatitis E virus (HEV) infection in acute non-A, non-B hepatitis in Greece. <i>Hepatology</i> , <b>1994</b> , 19, 1116	11.2	2
5	Seasonal variation in exacerbations of ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>1993</b> , 28, 95-6	2.4	43
4	Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis. <i>Gut</i> , <b>1993</b> , 34, S130-2	9.2	21

3	Acute delta hepatitis in Greek parenteral drug abusers. <i>Progress in Clinical and Biological Research</i> , <b>1993</b> , 382, 221-7		3
2	Treatment of acute non-A, non-B hepatitis with interferon alpha-2b. <i>Infection</i> , <b>1992</b> , 20, 242	5.8	3
1	Epidemiology and treatment of hepatitis E in the liver transplantation setting: A literature review. <i>Journal of Viral Hepatitis</i> ,		3-4